At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 368 enrolled
Drug / intervention
APD421 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting
In Brief
A Phase 3 clinical trial evaluating APD421 and Placebo for PONV. Completed, enrolled 368 participants across 2 sites in 2 countries.
Detailed Summary
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPONV
CountriesFrance, Germany
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedNov 2013
Primary CompletionJan 2014
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.6 years ago
Interventions
APD421drug
Placebodrug